Pfizer To Appeal Lipitor Patents In Norway
Pfizer Inc. plans to appeal a Norwegian appeals court decision that deemed its Lipitor patents invalid or uninfringed by Ranbaxy's generic version, the company said....To view the full article, register now.
Already a subscriber? Click here to view full article